#2013501
MDMA (eacstais)
MDMA (ecstasy)
MDMA (eacstais)
MDMA (ecstasy)
MDMA (eacstais): 5000 táibléad
MDMA (ecstasy): 5000 tablets
Úsáidtear MAMDPA chun 3,4-meitiléindé-ocsaifeinilprópán-2-ón (PMK) a tháirgeadh, agus is réamhtheachtaí é sin de chuid 3,4-meitiléindé-ocsaimeitilamfataimín (MDMA), rud a dtugtar “eacstais” air go coitianta.
MAMDPA is used to produce 3,4-Methylenedioxyphenylpropan-2-one (PMK), which, in turn, is a precursor of 3,4-methylenedioxymethamphetamine (MDMA), commonly known as ‘ecstasy’.
Is réamhtheachtaí 3,4-meitiléindé-ocsaifeiniolprópán-2-ón (PMK) é gliciodáit eitile PMK, a úsáidtear, ina dhiaidh sin, chun 3,4-meitiléindé-ocsaimeitiolamfataimín (MDMA) a tháirgeadh, ar a dtugtar “eacstais” de ghnáth.
PMK ethyl glycidate is a precursor of 3,4-Methylenedioxyphenylpropan-2-one (PMK), which, in turn, is used to produce 3,4-methylenedioxymethamphetamine (MDMA), commonly known as ‘ecstasy’.
Go gairid tar éis margadh inmheánach gan teorainn a chruthú, agus tar éis drugaí sintéiseacha amhail amfataimíní agus eacstais a theacht chun cinn agus a scaipeadh go tapa, ba léir go mbeadh teorainn le héifeachtacht na ngníomhaíochtaí náisiúnta agus gur ghá gníomhaíocht ón AE le leathadh substaintí díobhálacha a shrianadh.
Soon after a borderless internal market was created, and following the emergence and rapid spread of synthetic drugs, such as amphetamines and ecstasy, it became clear that the effectiveness of national actions is limited and that EU action was necessary to contain the spread of harmful substances.